The Technical Analyst
Verastem Inc [VSTM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Verastem Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.04% $11.07
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 280.02 mill |
| EPS: | -3.96 |
| P/E: | -2.80 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 25.30 mill |
| Avg Daily Volume: | 0.150 mill |
| RATING 2024-04-15 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.80 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.48x |
| Company: PE -2.80 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.690 (-84.73%) $-9.38 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 10.24 - 11.90 ( +/- 7.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Calkins Daniel | Sell | 6 | Common Stock |
| 2024-03-25 | Calkins Daniel | Sell | 25 | Common Stock |
| 2024-03-20 | Calkins Daniel | Sell | 55 | Common Stock |
| 2024-03-18 | Gagnon Robert E. | Sell | 283 | Common Stock |
| 2024-03-19 | Gagnon Robert E. | Sell | 130 | Common Stock |
| INSIDER POWER |
|---|
| 50.47 |
| Last 99 transactions |
| Buy: 1 037 036 | Sell: 241 539 |
Forecast:
16:00 - $11.12
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $11.12
Forecast 2: 16:00 - $11.12
Forecast 3: 16:00 - $11.12
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.07 (-2.04% ) |
| Volume | 0.117 mill |
| Avg. Vol. | 0.150 mill |
| % of Avg. Vol | 78.19 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VSTM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $13.39 | N/A | Active |
|---|
VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-04 07:30:00 - Press Release
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Boston--(business wire)--verastem oncology (nasdaq: vstm), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of its common stock to four new employees. the awards were granted pursuant to the nasdaq inducement grant exception as an inducement material to the employees' acceptance of employment with verastem oncology in accordance with nasdaq listing rule 5635(c)(4). the stock options ha.
2024-03-18 07:00:00 - Press Release
Global Patient Survey Results Reveal Significant Negative Impact On Social, Emotional And Mental Well-being For People Living With Low-grade Serous Ovarian Cancer
Boston--(business wire)--verastem oncology (nasdaq: vstm), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced new results from the first-ever global lgsoc patient impact survey, developed with patient advocates and community medical leaders to better understand and address the complex needs and experiences of those living with low-grade serous ovarian cancer (lgsoc). the results reveal a significant negative impact of lgsoc on respondents'.
2024-03-14 16:05:00 - Press Release
Verastem Oncology Reports Fourth Quarter And Full Year 2023 Financial Results And Highlights Recent Business Updates
Boston--(business wire)--verastem oncology (nasdaq: vstm), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended december 31, 2023, and highlighted recent progress. “in 2023, we made significant progress toward expanding the opportunities for avutometinib combination therapies across ras/mapk driven cancers and i am extremely proud of the team's accomplishments,” said dan paterson, pre.
2024-03-11 07:30:00 - Press Release
Verastem Oncology Announces Multiple Oral Presentations At Sgo 2024 Annual Meeting On Women's Cancer That Highlight Advances In Low-grade Serous Ovarian Cancer Research And Reinforce Commitment To Addressing Urgent Unmet Needs
Boston--(business wire)--verastem oncology (nasdaq: vstm), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced multiple oral and poster presentations, including a late-breaking oral presentation of avutometinib and defactinib combination from the ramp 201 part a trial in heavily pretreated patients with low-grade serous ovarian cancer (lgsoc), at the society of gynecologic oncology (sgo) 2024 annual meeting on women's cancer, to be held on.
2024-03-05 17:27:00 - Press Release
Verastem Oncology Receives Orphan Drug Designation From Fda For Avutometinib Alone Or In Combination With Defactinib In Recurrent Low-grade Serous Ovarian Cancer
Boston--(business wire)--verastem oncology (nasdaq: vstm), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the u.s. food and drug administration (fda) granted orphan drug designation (odd) to avutometinib, a raf/mek clamp, alone or in combination with defactinib, a selective fak inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer (lgsoc). “the fda orphan drug designation for avutometinib alone or in comb.
Latest News
2024-02-07 07:15:00 - InvestorPlace
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
In the vast landscape of today's markets, artificial intelligence (AI) is reshaping investment strategies. Therefore, AI stock picks are as relevant as ever.
2024-02-07 01:01:54 - Seeking Alpha
Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib
Rolling NDA submission of avutometinib + defactinib for the treatment of patients with low-grade serous ovarian cancer is expected in the 1st half of 2024, with possible commercialization in 2025. Results from two studies, RAMP-203 and RAMP-204, each using avutometinib with two different types of KRAS G12C inhibitors for the treatment of KRAS G12C NSCLC, expected mid-2024. The global non-small cell lung cancer market is expected to reach $38.8 billion by 2030; About 13% of NSCLC patients have the KRAS G12C mutation.
2024-01-22 09:16:04 - Zacks Investment Research
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.
2023-12-13 09:08:04 - InvestorPlace
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
As horror film fans know, there's safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth. Don't get me wrong – if you find yourself facing the market equivalent of a hockey-mask-wearing villain, you should probably consider the tried-and-true strength-in-numbers narrative.
2023-12-03 16:17:14 - InvestorPlace
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clarify, the ideas present tremendous risks.
2023-11-22 14:22:43 - InvestorPlace
3 Penny Stocks to Buy to Turn $1 into $100: November 2023
In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny stocks.
2023-11-22 13:32:47 - Zacks Investment Research
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-11-12 01:40:08 - Seeking Alpha
Verastem: Potential Accelerated Approval Filing In H1 2024
An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to keep avutometinib + defactinib for LGSC on the market or to convert Accelerated Approval to Full Approval. Company entered into a collaboration agreement with GenFleet Therapeutics to expand its pipeline and strengthen its position in the RAS driven cancer pathway space.
2023-10-04 21:00:20 - Seeking Alpha
Verastem: Signs Of Life For A Beaten-Down Equity
Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is being studied in various cancers, driven by RAS pathway activation, with promising early results in relapsed/refractory low-grade serous ovarian carcinoma. Verastem has sufficient cash to reach a new milestone in 2024 or early 2025, but more data is needed to determine if avutometinib is a viable solution in solid tumor oncology.
2023-09-05 07:00:00 - Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference; podium presentation on Tuesday, September 12, 2023 at 2:00 p.m. ET 2023 Cantor Global Healthcare Conference; fireside chat on Tuesday, September 26, 2023 at 9:55 a.m. ET A live webcast of the.